No new moves to compulsory licensing in China, say experts

A recent Reuters report has rung alarm bells about the prospect of compulsory licensing of pharmaceutical products in China. It claims that China is about to follow India, which has recently ordered Bayer to allow a generic version of its cancer…

Get unlimited access to all IAM content